<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0372741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3058</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin. Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Clinical pharmacology and therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0009-9236</issn>
<issn pub-type="epub">1532-6535</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30101418</article-id>
<article-id pub-id-type="pmc">6175613</article-id>
<article-id pub-id-type="doi">10.1002/cpt.1181</article-id>
<article-id pub-id-type="manuscript">NIHMS982490</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Modi</surname>
<given-names>Meera E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Translational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Childrenâ€™s Hospital, Harvard Medical School</aff>
<author-notes>
<corresp id="CR1">Corresponding author: Mustafa Sahin, <email>mustafa.sahin@childrens.harvard.edu</email>, 300 Longwood Ave, Boston, MA 02115, Tel: (617) 919-4518</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P12">CONFLICT OF INTEREST</p>
<p id="P13">MEM has no conflicts to declare. MS has served on the Scientific Advisory Board of Sage Therapeutics and PTEN Research Foundation and PTEN Hamartoma Tumor Syndrome Foundation. He also serves on the professional advisory board of the Tuberous Sclerosis Alliance. He has received research funding from Roche, Novartis, Pfizer, and LAM Therapeutics.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>12</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>104</volume>
<issue>4</issue>
<fpage>603</fpage>
<lpage>606</lpage>
<!--elocation-id from pubmed: 10.1002/cpt.1181-->
<kwd-group>
<kwd>autism</kwd>
<kwd>rare diseases</kwd>
<kwd>clinical trials</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>